iconEarnings Announcement After Market Close

Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:57 PM EDT
138.65quote price arrow up+7.75 (+5.92%)
Volume
376,782
Close
130.90quote price arrow up+4.24 (+3.35%)
Volume
810,719
52 week range
55.25 - 159.89
Loading...
  • Open127.06
  • Day High131.61
  • Day Low127.00
  • Prev Close126.66
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap12.371B
  • Shares Out94.51M
  • 10 Day Average Volume0.97M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change35.75

KEY STATS

  • Open127.06
  • Day High131.61
  • Day Low127.00
  • Prev Close126.66
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23
  • Market Cap12.371B
  • Shares Out94.51M
  • 10 Day Average Volume0.97M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change35.75

RATIOS/PROFITABILITY

  • EPS (TTM)-6.15
  • P/E (TTM)-21.28
  • Fwd P/E (NTM)76.24
  • EBITDA (TTM)-223.427M
  • ROE (TTM)-86.15%
  • Revenue (TTM)1.243B
  • Gross Margin (TTM)87.91%
  • Net Margin (TTM)-43.11%
  • Debt To Equity (MRQ)144.06%

EVENTS

  • Earnings Date05/01/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

 

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Bilal Arif
Executive Vice President - Strategy and Operations, Chief Technical Operations Officer
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NTRA
Natera Inc
94.15+1.27+1.37%
MEDP
Medpace Holdings Inc
397.86+9.51+2.45%
NBIX
Neurocrine Biosciences Inc
143.03+5.49+3.99%
EXAS
Exact Sciences Corp
60.01+0.66+1.11%
EXEL
Exelixis Inc
21.93-1.54-6.54%